These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27043285)

  • 1. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
    Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
    J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria.
    Kim H; Yang J; Kim MJ; Choi S; Chung JR; Kim JM; Yoo YH; Chung J; Koh H
    J Biol Chem; 2016 Jan; 291(4):1841-1853. PubMed ID: 26631731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
    Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
    Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
    Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
    Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
    Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
    Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
    Hsieh CC; Shen CH
    Curr Treat Options Oncol; 2019 Feb; 20(3):22. PubMed ID: 30778775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R; Morchon E; Martinez-Argudo I; Serrano R
    Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
    Corazao-Rozas P; Guerreschi P; André F; Gabert PE; Lancel S; Dekiouk S; Fontaine D; Tardivel M; Savina A; Quesnel B; Mortier L; Marchetti P; Kluza J
    Oncotarget; 2016 Jun; 7(26):39473-39485. PubMed ID: 27250023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
    Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
    J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.
    Khamari R; Trinh A; Gabert PE; Corazao-Rozas P; Riveros-Cruz S; Balayssac S; Malet-Martino M; Dekiouk S; Joncquel Chevalier Curt M; Maboudou P; Garçon G; Ravasi L; Guerreschi P; Mortier L; Quesnel B; Marchetti P; Kluza J
    Cell Death Dis; 2018 Feb; 9(3):325. PubMed ID: 29487283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
    Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.
    Barbato A; Iuliano A; Volpe M; D'Alterio R; Brillante S; Massa F; De Cegli R; Carrella S; Salati M; Russo A; Russo G; Riccardo S; Cacchiarelli D; Capone M; Madonna G; Ascierto PA; Franco B; Indrieri A; Carotenuto P
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.
    Agarwal E; Altman BJ; Seo JH; Ghosh JC; Kossenkov AV; Tang HY; Krishn SR; Languino LR; Gabrilovich DI; Speicher DW; Dang CV; Altieri DC
    J Biol Chem; 2019 Jul; 294(27):10407-10414. PubMed ID: 31097545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
    Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
    Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
    Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
    Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
    Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
    Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
    Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
    Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
    J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
    Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.